SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are cru...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2024-11, Vol.26 (11), p.2800-2811
Main Authors: López, Carlos López, Calvo, Mariona, Cámara, Juan Carlos, García-Paredes, Beatriz, Gómez-Martin, Carlos, López, Ana María, Pazo-Cid, Roberto, Sastre, Javier, Yaya, Ricardo, Feliu, Jaime
Format: Article
Language:English
Subjects:
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Clinical Guides in Oncology
Combined Modality Therapy
Humans
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Medical Oncology
Medicine
Medicine & Public Health
Neoplasm Staging
Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A.
ISSN:1699-3055
1699-048X
1699-3055
DOI:10.1007/s12094-024-03568-4